American CRO Charles River Reacts To Global Crisis, Falling Profits With Plans To Close One U.S. Facility While Expanding In China
This article was originally published in The Pink Sheet Daily
Executive Summary
Charles River is "now the leading international CRO in China with GLP capabilities," CEO Foster told investors and analysts on May 6.
You may also be interested in...
Global Financial Crisis Could Speed Up Sending Pharma Research To China
BEIJING - The financial crisis ricocheting across the United States and Europe could cut into R&D funding by the globe's top pharmaceutical powers, but is also likely to trigger sending more drug research to Chinese scientists, according to industry insiders and analysts
China Emerging As Big Winner In Pharma Outsourcing Rush To Asia - PwC
BEIJING - Asia's expanding wealth and markets for drugs, combined with a pool of scientific talent and strengthening protections for patents, are propelling pharmaceutical multinationals to step up operations in the region in drug manufacturing, research and clinical trials
Bayer Schering Partners With Polish Biotech Firm To Provide Recombinant Insulin To China's Exploding Diabetics Population
Bayer's antidiabetes drug Glucobay (acarbose), an alpha-glucosidase inhibitor, is already one of the company's strongest products in China.